TG Therapeutics Q1 2023 Earnings Report
Key Takeaways
TG Therapeutics reported its Q1 2023 financial results, marked by the commercial launch of BRIUMVI, which generated $7.8 million in net sales during its first partial quarter. The company's net loss was $39.2 million, and it holds cash, cash equivalents, and investment securities totaling $139.7 million.
BRIUMVI net sales reached $7.8 million in the first partial quarter.
Over 400 BRIUMVI prescriptions were written by 165+ healthcare providers at 125+ centers.
Payor coverage is in place for over 50% of covered lives for BRIUMVI.
Net loss for the quarter was $39.2 million.
TG Therapeutics
TG Therapeutics
Forward Guidance
TG Therapeutics anticipates that its cash, cash equivalents and investment securities as of March 31, 2023, combined with $20.0 million of available capacity under its existing term loan facility and projected revenues, will be sufficient to fund its planned operations into mid-2024.